chang recommend
downgrad get pain
downgrad share walgreen outperform
end one pain experi endur
year sell-sid analyst typic hate reactiv downgrad least
wait day post news case
realli struggl put togeth coher thesi
outperform post pillpack news certainli
camp believ emerg massiv threat
pharmaci overnight even medium long term
howev see continu risk front end believ
market suffici amount worri long-term margin
mean termin valu could remain impair reflect
compress multipl current wall worri simpli high
climb view risk join drug price uncertainti front
end eros eu fee pressur brexit volatil furthermor sell
side estim still appear high year oi
perspect consensu impli return profit growth
beyond wrong algorithm view thu number
go may go long litani potenti headwind
unlik de-risk medium term thu keep multipl
impair one actual get improv return that
ultim question could answer thu move
sidelin
wrong everyon make mistak think mom
taught key said alway learn error
appli teach go forward case rate
quit simpl put trust manag creat
massiv valu other entir profession life could
navig global retail distribut entiti confluenc
storm come side still gener substanti cash flow
return also believ market would skeptic
entri pharmaci turn would discount massiv
undertak would involv go zero meaning market share
highli competit clinic orient industri larg
entrench competitor clearli wrong assumpt
investor acquisit revenu entiti
caus panic introduc bear thesi difficult
disprov best take year unwind furthermor stefano
team done reason job strateg move clear
bia toward partnership jv vs outright acquisit healthcar
servic entiti elong transform chang thesi allow
continu concern exist profit particularli per squar
foot basi main conclus draw
market becom fixat long term profit risk
mosaic allow increas doubt especi current underli
fundament mix find bottom valuat bit
futil exercis debat termin valu
highli sensit histor bia solid manag goe
window
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
stefano didnt becom bad steward capit overnight still might proven correct said done
year turn look improv mosaic solid proof point engag construct basi see
littl evid today compel consist remind thesi dont much els
point order convinc broader audienc slope declin manag market current
perceiv thu revers error oppos consist wrong next twelv month
updat think underli fundament term us busi stori superior top line share gain
rx specialti contribut offset front end comp declin hamper reimburs mix gross margin
line strong cost manag allow msd oper incom growth challeng go forward impli share loss
part turn store rx flat neg sever qs front end remain challeng due sku ration share
loss synergi like slow ramp despit uptick store close suggest oi growth
slow lsd organ basi like turn neg modest contribut drive total
report growth slightli posit unclear turn dynam around opportun share
recaptur present yet market also question long cost cut off-set gp deterior certainli
perpetu make matter wors underli fundament intern retail alreadi challeng top
see unfavor currenc mix yet thu oper profit growth alreadi difficult despit fx tailwind
like remain mute pressur growth algorithm lastli wholesal busi offer stabil
continu boost contribut whole larg enough off-set challeng seen elsewher roll
modest oper profit growth pictur without much upsid risk unless dollar weaken
ep primarili driven sizeabl repurchas author dynam clearli fulli appreci
sell-sid continu see msd oi growth entiti overal ep growth possibl
see hsd ep growth think msd oi go major challeng near imposs unless circumst chang
strategi option market taken wait see skeptic approach much
announc vertic integr contend long term orient sharehold still prefer healthcar centric box vs
tradit conveni beauti bia also prefer certainti state strategi vs trust approach
said tough contempl larg transform transact read requir equiti stock disloc pe
deflat limit wba action set transact materi us distribut anyon turn argu pursu
partnership jv rout vs outright acquisit may end reason approach capit return also far
complex requir mani small relationship grow sizeabl one vs clear state approach
control entir entiti also complex cost first accru box given need invest
major benefit goe cost trend sort proper econom financi incent furthermor
jv partnership approach also elong period inflect new healthcar servic centric strategi given
current state sentiment like challeng thu expect grow set relationship servic vendor
la labcorp unit health unfortun expect street remain skeptic obviou increment
contribut boost growth sustain margin furthermor jv partnership structur also typic less transpar
also may argu whatev progress gain made difficult attribut specif strategi ultim
see silver bullet share strateg optim longer period would argu
purchas longer given multipl dispar
 pillpack realli threat remain skeptic time-frame abl ramp pillpack
modestli competit pharmaci undeni enter market bring question
long term margin price vs share view best case scenario medium-term see morph
like entiti market share minim feat would requir ramp revenu
nearli howev would contend much share like come mail home deliveri fit well
chronic patient cash pay market mail loss like littl impact compress
cash margin share could materi ep despit modest size work suggest share loss
margin compress cash high volum gener could yield north cut ep pain driven
fact much box econom fix thu traffic share price flow decrement margin
pain term dcf chosen moder revenu growth lsd impli slight share loss trend long
term margin use perp growth arriv price target take modest market share
model put margin supposedli target na busi pt would fall w/ perp
growth took perp growth would impli share could bottom thu see downsid risk
like manag view issu see downsid scenario analysi possibl target
littl neg margin earli effort gain market share potenti disrupt
contempl would suggest less construct view given evid risk argu fit treatment
bull case thu tabl see rate appropri
increasingli common question cant close box time concept shrink physic squar
footag hot topic late given impli pressur box econom broadli decid dig interestingli
current own locat outright us retail respect thu question
realli becom one leas futur liabil accord wba latest compani compani today
oper leas balanc sheet furthermor liabil relat alreadi announc store close north
doubl recent trend given elev focu close essenti present valu futur rent
oblig first leas option date note us leas year renew option year interv
non-u leas much shorter durat thu look wba oper leas liabil nearli sit outsid
year main issu obviou degre manag want need shrink
store base quickli would pain exercis thu impli yield isnt particularli case
eventu assum box econom deterior rate close becom sensibl argu realiti
real estat pictur optimist could present anoth avenu improv growth return help
off-set long term threat on-line competit furthermor push concept transit
box product healthcar servic key
could wrong sometim obviou question answer singl key debat point
mani item play flux doubt front end trend improv materi thu us busi would
case share gain possibl post vertic merger model world clearli prefer mani relationship open
model vs close turn may appeal initi broader audienc fear integr entiti furthermor
possibl drug price debat come mute conclus point seem like get wors better final
doubt manag revers cours materi healthcar claim defeat pharmaci write invest
pillpack thu tough see de-risk although would note food retail ralli post initi freak
share howev food inflat improv key metric well save grace buy-back
help put floor share least provid natur outright buyer market conclus contra case
super compel thu state initi coher bull case center valuat tough articul
furthermor neg side guess could hope continu multipl degrad modest ep downsid
set seem argu sizeabl downsid bet rel could anoth matter
lastli dont forget tune webinar today go thought et
link webinar
walgreen stat million except per share data fy end august usa pharmaci usa fe total cc sale total cc sale growth revenu margin growth revenu ep share net incom price-to-earnings premium/discount isi healthcar technolog distribut juli
pt equat forward cy ep dcf tgr
downsid risk potenti on-line competit amazon erod front end comp margin us
pharmaci share continu reimburs pressur us eu hit ultim lead total margin compress
transact prove challeng increas volum revenu store appear futil lead poor return posit
independ retail us becom disadvantag vertic integr peer capabl take notabl share manag
unabl locat creativ transact leav balanc sheet underutil limit total oper growth beauti push
ultim becom distract momentum build manag must revisit costli rebuild store format
laboratori corp america hold
articl articl
time dissemin juli et
analyst ross muken elizabeth anderson suzi yoon primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view
